| |||||||||
Type Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Donating Investigator Frank Chisari, Scripps Research Institute Appearance
black
Related Genotype: a/aDescription
This strain is referred to as "50-4" or "Tg(Alb1-HBV)Bri44" in the primary reference.
| Control | ||
|---|---|---|
| Noncarrier female | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Strains carrying other alleles of Alb
007853 129S/SvEv-Tg(Alb1-Ren)1Unc/CofJ 007238 B6.Cg-Tg(Alb-PLG)1Dgi/J View Strains carrying other alleles of Alb (2 strains)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Tg(Alb1HBV)44Bri/0
involves: C57BL/6
- tumorigenesis
- hepatoma (MGI Ref ID J:86165)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Apoptosis Research
Death Receptors
Cancer Research
Genes Regulating Growth and Proliferation
Growth Factors/Receptors/Cytokines
Increased Tumor Incidence (Hepatomas: hepatacellular carcinoma)
Virology Research
Hepatitis B Virus
| Allele Symbol | Tg(Alb1HBV)44Bri | ||
|---|---|---|---|
| Allele Name | transgene insertion 44, Ralph L Brinster | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 50-4; 50.4; HBs-tg; HBsAg; Tg(Alb1-HBV)Bri44; | ||
| Mutation Made By | Frank Chisari, Scripps Research Institute | ||
| Expressed Gene | HBV, hepatitis B virus large envelope polypeptide, | ||
| Promoter | Alb, albumin, mouse, laboratory | ||
| Molecular Note | Sequence encoding the hepatitis B virus large envelope polypeptide was placed downstream of the mouse albumin promoter, thereby expressing the peptide in hepatocytes. [MGI Ref ID J:86165] | ||
Genotyping Protocols
Tg(Alb1HBV)44Bri, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Chisari FV; Klopchin K; Moriyama T; Pasquinelli C; Dunsford HA; Sell S; Pinkert CA; Brinster RL; Palmiter RD. 1989. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59(6):1145-56. [PubMed: 2598264] [MGI Ref ID J:86165]
McGlynn KA; Hunter K; LeVoyer T; Roush J; Wise P; Michielli RA; Shen FM; Evans AA; London WT; Buetow KH. 2003. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 63(15):4594-601. [PubMed: 12907637] [MGI Ref ID J:85696]
Singh M; Kumar V. 2003. Transgenic mouse models of hepatitis B virus-associated hepatocellular carcinoma. Rev Med Virol 13(4):243-53. [PubMed: 12820186] [MGI Ref ID J:84502]
Tg(Alb1HBV)44Bri relatedBao JJ; Lee BP; Stephens LC; Sahin AA; Van NT; Johnston DA; Ou CN; Kuo MT. 2000. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein Mol Carcinog 29(2):103-11. [PubMed: 11074607] [MGI Ref ID J:66205]
Barone M; Spano D; D'Apolito M; Centra M; Lasalandra C; Capasso M; Di Leo A; Volinia S; Arcelli D; Rosso N; Francavilla A; Tiribelli C; Iolascon A. 2006. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med 12(4-6):115-23. [PubMed: 16953557] [MGI Ref ID J:115973]
Chemin I; Ohgaki H; Chisari FV; Wild CP. 1999. Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver 19(2):81-7. [PubMed: 10220736] [MGI Ref ID J:91033]
Chen Y; Wei H; Sun R; Tian Z. 2005. Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. Int Immunopharmacol 5(13-14):1839-52. [PubMed: 16275620] [MGI Ref ID J:103638]
Chisari FV; Filippi P; Buras J; McLachlan A; Popper H; Pinkert CA; Palmiter RD; Brinster RL. 1987. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A 84(19):6909-13. [PubMed: 3477814] [MGI Ref ID J:94462]
Crawford DR; Ostrowski S; Vakharia D; Ilic Z; Sell S. 2006. Separate Origins of Hepatitis B Virus Surface Antigen-Negative Foci and Hepatocellular Carcinomas in Transgenic HBsAg (alb/psx) Mice. Am J Pathol 169(1):223-32. [PubMed: 16816375] [MGI Ref ID J:110171]
Dunsford HA; Sell S; Chisari FV. 1990. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 50(11):3400-7. [PubMed: 1692259] [MGI Ref ID J:101631]
Ghebranious N; Sell S. 1998. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 27(2):383-91. [PubMed: 9462635] [MGI Ref ID J:47062]
Ghebranious N; Sell S. 1998. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 27(4):967-73. [PubMed: 9537435] [MGI Ref ID J:47088]
Huang SN; Chisari FV. 1995. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 21(3):620-6. [PubMed: 7875658] [MGI Ref ID J:90880]
Kaplanski C; Chisari FV; Wild CP. 1997. Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis 18(4):633-9. [PubMed: 9111192] [MGI Ref ID J:39821]
Kuo MT; Zhao JY; Teeter LD; Ikeguchi M; Chisari FV. 1992. Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ 3(8):531-40. [PubMed: 1356418] [MGI Ref ID J:3153]
Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL. 2007. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132(4):1465-75. [PubMed: 17433324] [MGI Ref ID J:128326]
McGlynn KA; Hunter K; LeVoyer T; Roush J; Wise P; Michielli RA; Shen FM; Evans AA; London WT; Buetow KH. 2003. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 63(15):4594-601. [PubMed: 12907637] [MGI Ref ID J:85696]
Qu X; Yu J; Bhagat G; Furuya N; Hibshoosh H; Troxel A; Rosen J; Eskelinen EL; Mizushima N; Ohsumi Y; Cattoretti G; Levine B. 2003. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112(12):1809-20. [PubMed: 14638851] [MGI Ref ID J:86953]
Reifenberg K; Hildt E; Lecher B; Wiese E; Nusser P; Ott S; Yamamura K; Rutter G; Lohler J. 2006. IFNgamma expression inhibits LHBs storage disease and ground glass hepatocyte appearance, but exacerbates inflammation and apoptosis in HBV surface protein-accumulating transgenic livers. Liver Int 26(8):986-93. [PubMed: 16953839] [MGI Ref ID J:135035]
Roh S; Kim K. 2003. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells. Microbiol Immunol 47(6):453-60. [PubMed: 12906106] [MGI Ref ID J:127655]
Schirmbeck R; Dikopoulos N; Kwissa M; Leithauser F; Lamberth K; Buus S; Melber K; Reimann J. 2003. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol 33(12):3342-52. [PubMed: 14635042] [MGI Ref ID J:87140]
Sun D; Ren H; Oertel M; Sellers RS; Zhu L. 2007. Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. Carcinogenesis 28(9):1859-66. [PubMed: 17434927] [MGI Ref ID J:125423]
Trobonjaca Z; Kroger A; Stober D; Leithauser F; Moller P; Hauser H; Schirmbeck R; Reimann J. 2002. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 168(8):3763-70. [PubMed: 11937527] [MGI Ref ID J:126190]
Wiemann SU; Satyanarayana A; Buer J; Kamino K; Manns MP; Rudolph KL. 2005. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 24(9):1501-9. [PubMed: 15608677] [MGI Ref ID J:96885]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| Noncarrier female | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.